So based upon the recent ruling of Myriad Genetics (NASDAQ: MYGN) invalidation of certain patents covering the BRCA1 and BRCA2 genes, I was planning on levering the news as fodder for an all out April Fools’ post effort, likely to have been something along the lines of ‘10,000 Gene-based Patents Overturned, Biotechnology Industry Implodes’. A [...]